Although Apo B was significantly down regulated in the 2nd phase, it was not considered for the validation phase since it is known that statin decreases the levels of Apo B25, 26 and most of the CAD cases in our study were consuming statins. This evidence concerns the gene APOB and coronary artery disorder.